



**GYNECOLOGIC CANCER INTERGROUP (GCI)  
TRANSLATIONAL RESEARCH COMMITTEE MEETING**

**CHAIR: CLARE SCOTT CO-CHAIR: CHARLIE GOURLEY PAST CHAIR: IAIN MCNEISH  
HARMONIZATION LIAISONS: N.LEFUR/A.NEGROUK (OPS); M.BRADY/D.TU (STATS)**

**MINUTES**

**Topics:**

**Long-term Olaparib (OLALA)**

Provided background about role of olaparib in high-grade serous ovarian cancers. Concept of super-responders in bladder cancer (everolimus) and BRAF-mutant melanoma (BRAFi or MEKi). Super-responders from study 19 and study 41, who received maintenance olaparib for HGSC. In order to focus on the patients who have been on olaparib or survived post olaparib for >2 years, with or without ongoing drug, with or without relapse, can be included in a molecular study, OLALA. Can be opened at any institution, patients consented, blocks obtained and other tissue/blood collected. Samples sent to COVANCE for central analysis. Additional treatment study for post-olaparib treatment available.

**Stephanie Lheureux (PMHC)**

**Uterine Lavage for diagnosing EOC: an update**

Use of uterine lavage via catheter, well tolerated, no anaesthetic required, lavage fluid analysed for p53 mutation (very low level in patients with benign conditions), higher in patients with STIC and cancer. One cancer detected so far, no stage shift but may have lower burden of disease. Multiple groups now involved. Broad molecular analysis underway. More patients being accrued and screened.

**Paul Speiser (AGO)**

**Translational Research and immune profiling**

Description of RAIDS, ever expanding, Whole exome data on 50 cervical cancer cases at diagnosis and targeted sequencing of 140 cases. Aiming for relapse pairs. ctDNA analysis for PIK3CA coming along. IHC (immune, stromal, endothelial, NKI, Amsterdam) for tumour microenvironment, RPPA planned. Twenty cell lines from previous cases (20 commercially available): whole exome analysis, compared with TCGA. Screened cell lines for synthetic lethality (>40drugs, classical and targeted).

**S.Scholl (EORTC)**

**Immune profiling in High-grade serous ovarian cancer**

Brief presentation of potential role of immunotherapies in solid tumour. Expression analysis of TILs in ovarian cancer. TCR reported in ASCITES and Tumor. Neoantigens have important role to improve PD1 and CTLA4 blockade. Longer session next meeting.

**Kosei Isagawa (GOTIC)**

**Implications of panel testing in gynaecologic cancer**

Need for molecular profiling across solid tumours to stratify patients for clinical trial entry. Not only sequencing of relevant genes (often not so relevant for HGSC, although can be in LGS, LGE, mucinous OC), but also oncogenic amplifications and TSG deletions. Examples of Foundation Medicine panel testing at

**Clare Scott (ANZGOG)**

diagnosis versus relapse. Importance of amplifications/deletions. Need to coordinate / define helpful approaches, also for immunoprofiling / immunoscore (particularly as each company has their own drug and their own diagnostic). Will focus on this in November 2015 and also in Lisbon, November 2016.

**Molecular profiling in high-grade serous ovarian cancer**                      **Charlie Gourley (UK)**

Update of his microarray analysis of HGSC, revealing an “immune high”, good prognosis subset, across four HGSC databases and two other tumour types. Now has the German ICON7 data to analyse the Bev effect by his profile. Described the ICON12 design, randomised first-line, major division into HR defective vs not; HRD randomised into IP vs IV cisplatin (olaparib could be added to both arms later, plus or minus an immune therapy); non-HRD analysed by profiling into immune high (immune therapies) versus angio high (anti-angiogenic therapy). Aiming for focus on tissue, ctDNA and a lot of translation.

**Global MTA update**    **Nathalie Le Fur (Harmonization) & Clare Scott (ANZGOG)**

Description of need for and development of new Material and Services Transfer Agreement; one for GCIG as sponsor with each group as providers; second for researcher as sponsor and multiple labs as providers of tissue, especially designed for rare tumour research (to be presented at the IRCI Board meeting). Aim for tissue to be available for future studies with streamlined governance. Definitions. No change of ownership / IP. Authorship governed by IJCME 4 criteria (providing samples or derivatives is not sufficient to warrant co-authorship).

**Translational Brainstorming Day in Lisbon in November 2016. Planning committee initiated, met, exploring main themes. Call for those interested in being involved to contact Chair.**